10-Q: Definitive Healthcare Reports Q1 2026 Results, Faces Revenue Decline

Definitive Healthcare Corp. reported a decrease in revenue for the first quarter of 2026, citing sales execution challenges and macroeconomic headwinds, while also recording a significant goodwill impairment charge.

Summary

• Definitive Healthcare Corp. reported a 6% decrease in revenue for the first quarter ended March 31, 2026, totaling $55.9 million, compared to $59.2 million in the same period of 2025.
• The company recorded a substantial goodwill impairment charge of $197.2 million in Q1 2026, compared to $176.5 million in Q1 2025.
• Operating expenses increased by 6% to $242.9 million, largely due to the goodwill impairment charges.
• Net loss attributable to Definitive Healthcare Corp. widened to $138.6 million from $107.2 million in the prior year period.
• The company experienced a decrease in customer count, with Enterprise Customers declining by 17 to 495.
• Management expects revenue to decline in 2026 compared to 2025 due to ongoing sales execution challenges and macroeconomic conditions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, widening losses, customer attrition, and significant goodwill impairment, despite some operational efficiencies shown in adjusted metrics.

Positives

• Despite revenue decline, professional services revenue increased by $0.5 million.
• Cost of revenue decreased by 7% due to favorable renegotiations on data contracts and amortization of certain data assets.
• The company maintained compliance with its debt covenants.
• Adjusted EBITDA increased slightly to $15.3 million from $14.7 million, with an improved Adjusted EBITDA Margin of 27% from 25%.

Negatives

• Revenue decreased by 6% to $55.9 million in Q1 2026.
• Net loss attributable to Definitive Healthcare Corp. increased to $138.6 million.
• Total customer count decreased to approximately 2,260 from 2,475 year-over-year.
• Enterprise Customer accounts decreased by 17 to 495.
• Significant goodwill impairment charges of $197.2 million were recorded in Q1 2026.
• The company expects continued revenue decline in 2026.

Risks

• Continued impact of sales execution challenges and macroeconomic headwinds on revenue growth.
• Elevated customer churn, particularly among smaller customers and in the Life Sciences market.
• Potential negative impact on data acquisition prices due to changes in the healthcare claims data market.
• Risks associated with global macroeconomic conditions, including inflation, high interest rates, and geopolitical tensions.
• Uncertainty in the ultimate outcome of litigation regarding contingent consideration for a prior acquisition.
• Potential for increased operating expenses due to inflation, particularly in labor costs.

Future Outlook

The company expects revenue to decline in 2026 compared to 2025 due to ongoing sales execution challenges and macroeconomic headwinds. Management anticipates continued investment in cost of revenue, potentially leading to a modest increase in cost of revenue as a percentage of revenue. The company expects gross profit margin to decrease in 2026 due to revenue declines and a largely fixed cost structure, as well as the non-recurrence of one-time credits received in fiscal year 2025.

Management Comments

• "These changes created disruptions to our sales efforts beginning in 2024, impacting both new customer acquisition and upsell to existing customers. These factors, in addition to the lower than historical renewal rates we observed through fiscal year 2025, have impacted, and we expect will continue to impact, our results in 2026."
• "However, late in 2025, we began seeing modest signs of improvement in the macroeconomic backdrop, with healthier demand trends, more normalized procurement cycles, improving customer retention dynamics, and increased visibility into customer budgets, all of which are encouraging signs we will continue to monitor."
• "We believe that our cash flow from operations, availability under the 2021 Credit Agreement and available cash and cash equivalents and short-term investments will be sufficient to meet our liquidity needs for at least the next twelve months and in the long term."

Industry Context

StockSavvy.ai notes that Definitive Healthcare operates in the competitive healthcare data and analytics sector. The company's performance is significantly influenced by macroeconomic conditions affecting customer spending, particularly in the Life Sciences and Provider markets. The reported revenue decline and customer churn align with broader industry trends of increased caution in enterprise spending and a focus on operational efficiency.

Comparison to Industry Standards

• The reported revenue decline of 6% for Q1 2026 is concerning when compared to the typical growth rates expected in the SaaS and data analytics sectors, which often aim for double-digit annual growth.
• The significant goodwill impairment charge of $197.2 million suggests a substantial overvaluation of past acquisitions or a significant decline in the expected future performance of acquired assets, which is a negative indicator compared to companies with stable or growing goodwill balances.
• The Adjusted EBITDA margin of 27% is a positive indicator of operational efficiency, but it is crucial to monitor if this can be sustained or improved amidst declining revenues and increasing costs.
• Competitors like IQVIA and Clarivate Analytics also operate in the healthcare data and analytics space, and their recent performance would provide a benchmark for Definitive Healthcare's challenges and opportunities.

Management Changes

Legal Proceedings

• The company is involved in litigation regarding contingent consideration for a prior acquisition, where former equity holders assert that performance conditions were met at a higher payout tier than calculated by the company.

Related Party Transactions

• Recorded $0.2 million in revenue from entities affiliated with its Sponsors and members of the Board during the three months ended March 31, 2026 and 2025.
• Had receivables of $0.1 million from related parties as of March 31, 2026.
• Paid $0.6 million to related parties during the three months ended March 31, 2026, and $0.3 million in the same period of 2025.
• Had payables to related parties of $0.3 million as of March 31, 2026.

Stakeholder Impact

• Shareholders: Negative impact due to declining revenue, widening net loss, and significant goodwill impairment, which could lead to a decrease in share price. The expectation of continued revenue decline also poses a risk.
• Employees: Potential impact from workforce reduction of approximately 40 people as part of the 2026 Restructuring Plan.
• Customers: While not directly stated, increased churn and sales execution challenges could lead to a perception of instability, though the core data and analytics platform remains a key offering.
• Creditors: The company remains compliant with debt covenants, and its liquidity appears sufficient for the next twelve months, suggesting a stable outlook for creditors in the short term.

Next Steps

• Continue to monitor macroeconomic backdrop for signs of improvement in demand trends, procurement cycles, and customer retention.
• Continue to renegotiate existing data contracts and add new data sources to mitigate potential impacts on data acquisition costs.
• Continue to invest in product development, systems optimization, and AI to enhance data quality and insights.
• Evaluate strategic acquisitions and investments that further expand the platform.
• Continue to manage operating expenses, including workforce reductions as part of restructuring plans.

Key Dates

Recommendation

While the company faces significant headwinds with declining revenue, widening losses, and substantial goodwill impairment, its Adjusted EBITDA shows some resilience, and it maintains sufficient liquidity. The expectation of continued revenue decline warrants caution, but the core business in healthcare data analytics remains essential. A 'hold' recommendation reflects the uncertainty and the need to see evidence of stabilization and a return to growth before considering a more positive stance.

Keywords

Definitive Healthcare, 10-Q, Quarterly Report, Healthcare Data, Analytics, Revenue Decline, Goodwill Impairment, Financial Results, SEC Filing, Subscription Revenue